PENNY WATCH

[crazy horse 0]

Tonix Pharmaceuticals to Present at 16th Annual Sachs Biotech in Europe Forum

Click Here for more Tonix Pharmaceuticals Holding Charts.

Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present at the 16th Annual Biotech in Europe Forum being held on September 27-28, 2016 in Basel, Switzerland by Sachs Associates.

Ronald Notvest, Ph.D., Executive Vice President, Commercial Planning and Development at Tonix, will provide a corporate update and an overview of Tonix’s PTSD clinical program. Tonix recently announced a successful end-of-phase 2 meeting with the U.S. Food and Drug Administration (FDA) and also positive data from its randomized, double-blind, placebo-controlled Phase 2 AtEase clinical trial evaluating TNX-102 SL in military-related PTSDDr. Notvest will discuss expected next steps for this program..
Event: Sachs 16th Annual Biotech in Europe Forum
Date: Tuesday, September 27, 2016
Time: 4:45pm CEST (Central European Summer Time)
Location: Presentation Track G: Darwin Room, Congress Center, Basel, Switzerland

TNX-102 SL is an Investigational New Drug and has not been approved for any indication.

About Tonix Pharmaceuticals Holding Corp.

http://ih.advfn.com/p.php?pid=nmona&article=72521369&symbol=TNXP